Evidence map›Paper›PMID 28042618›Full record

ArticleAnnals of clinical cytology and pathology2016

Human Papillomavirus at Multiple Sites Associated with Anal Squamous Intraepithelial Lesions in HIV-Seropositive Individuals.

Eleanore Chuang, Eunjung Lim, Cris Milne, Xuemei Zhu, Melissa Agsalda, Jeffrey Killeen, F DeWolfe Miller, Brenda Y Hernandez, Bruce Shiramizu

Abstract read
In one paragraph

Article in Annals of clinical cytology and pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eleanore ChuangHawaii Center for AIDS, John A. Burns School of Medicine, University of Hawaii, USA; Department of Tropical Medicine, Medical Microbiology & Pharmacology, John A. Burns School of Medicine, University of Hawaii, USA.
Eunjung LimOffice of Biostatistics and Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii, USA.
Cris MilneHawaii Center for AIDS, John A. Burns School of Medicine, University of Hawaii, USA.
Xuemei ZhuUniversity of Hawaii Cancer Center, USA.
Melissa AgsaldaHawaii Center for AIDS, John A. Burns School of Medicine, University of Hawaii, USA; Department of Tropical Medicine, Medical Microbiology & Pharmacology, John A. Burns School of Medicine, University of Hawaii, USA.
Jeffrey KilleenUniversity of Hawaii Cancer Center, USA; Department of Pathology, John A. Burns School of Medicine, University of Hawaii, USA.
F DeWolfe MillerDepartment of Tropical Medicine, Medical Microbiology & Pharmacology, John A. Burns School of Medicine, University of Hawaii, USA.
Brenda Y HernandezDepartment of Tropical Medicine, Medical Microbiology & Pharmacology, John A. Burns School of Medicine, University of Hawaii, USA; University of Hawaii Cancer Center, USA; Department of Pathology, John A. Burns School of Medicine, University of Hawaii, USA.
Bruce ShiramizuHawaii Center for AIDS, John A. Burns School of Medicine, University of Hawaii, USA; Department of Tropical Medicine, Medical Microbiology & Pharmacology, John A. Burns School of Medicine, University of Hawaii, USA.

Funding

UH Hilo COP A&RP20GM103466 · NIGMS · UNIVERSITY OF HAWAII AT MANOA · PI Peter R Hoffmann · 2012 to 2026
$60.3M
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Xin Chen · 1996 to 2026
$56.2M
University of Southern CaliforniaU01CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KROWN, SUSAN E · 2006 to 2014
$54.7M
RESEARCH DESIGN AND BIOSTATISTICS COREU54MD007584 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI MOKUAU, NOREEN, SHIRAMIZU, BRUCE T · 2012 to 2018
$21.1M
University of Guam/Cancer Research Center of Hawaii Partnership (1 of 2)U54CA143727 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI LYNNE R WILKENS · 2009 to 2026
$19.1M
WILLINGNESS OF PRIMARY CARE PHYSICIANS TO ADOPT HANDHELD COMPUTINGP20RR011091 · NCRR · UNIVERSITY OF HAWAII AT MANOA · PI ERDEM, GULIZ · 1995 to 2009
$16.5M
RESEARCH DESIGN, BIOSTATISTICS AND RESEARCH ETHICS COREG12MD007601 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI BERRY, MARLA J · 2012 to 2016
$13.0M
RESEARCH ETHICSU54RR026136 · NCRR · UNIVERSITY OF HAWAII AT MANOA · PI SETO, TODD B · 2010 to 2011
$8.5M
Univ. of Guam/Cancer Res. Center of Hawaii PartnershipU56CA096254 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI VOGEL, CARL-WILHELM E · 2003 to 2009
$1.5M
NCI NIH HHS P30 CA071789NCI NIH HHS U01 CA121947NCI NIH HHS U54 CA143727NCI NIH HHS U56 CA096254NCRR NIH HHS P20 RR011091NCRR NIH HHS U54 RR026136NIGMS NIH HHS P20 GM103466NIMHD NIH HHS G12 MD007601NIMHD NIH HHS U54 MD007584
6 · The paper itself

Abstract

objectiveHIV-Seropositive patients have higher risk of HPV infection even on anti-retroviral therapy. Infection with high-risk HPV genotypes can cause dysplasia leading to cancer. This study assessed HPV at different anatomical sites in HIV-seropositive individuals and factors associated with anal squamous intraepithelial lesions (ASIL).

methodsSpecimens were obtained from multiple anatomical sites for each participant in conjunction with routine screening for anal dysplasia. Female specimens included cervical and anal cytologies and oral wash. Male specimens included anal cytologies, oral wash, and exfoliated cells from penile head, penile shaft, scrotum, and from uncircumcised subjects, inner foreskin. Demographic and clinical characteristics were recorded. Following DNA extraction, HIV DNA copy was assessed by qPCR; HPV was genotyped. Statistical analyses included calculation of odds ratios (OR) and 95% confidence intervals (CI), t-tests or Mann-Whitney tests.

resultsMales were more likely to have ASIL: 29/50 (58%) compared to 1/11 females (9%) (OR=13.81, 95% CI: 1.64-116.32). HPV 6 or 11 in anal specimens was significantly associated with ASIL (OR= 6.29, 95% CI: 1.49-26.44). Number of HPV genotypes in anal specimens was also significant: ASIL+ (3.4 ± 3.1) versus ASIL- (1.6 ± 3.1) (p=0.009). Among 44 males, HPV was detected from at least one anatomical site for 33 participants (75%): 27 anus (61%), 19 oral wash (44%), 17 penile shaft (39%), 11 scrotum (26%), 10 penile head (23%), 0 foreskin. Detection of HPV in penile shaft specimens was significantly associated with ASIL (OR=6.79, 95% CI: 1.57-29.36) as was number of HPV genotypes in penile shaft specimens: ASIL+ (2.4 ± 4.0) versus ASIL- (0.6 ± 1.7) (p=0.025). Only 1/11 females had ASIL; only 1/11 females had cervical dysplasia: OR was not estimable due to small numbers.

conclusionsMales were more prone to ASIL than females. HPV at anal as well as non-anal sites may be indicative of ASIL.

Indexed as

Anal cancerAnal dysplasiaHIVHPVHuman immunodeficiency virusHuman papillomavirus

Identifiers

PMID28042618
PMCPMC5198841

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.